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Abstract
Objective: Clinical and genetic predictors of response to antiepileptic drugs (AEDs) 
are largely unknown. We examined predictors of lacosamide response in a real‐world 
clinical setting.
Methods: We tested the association of clinical predictors with treatment response 
using regression modeling in a cohort of people with refractory epilepsy. Genetic as-
sessment for lacosamide response was conducted via genome‐wide association stud-
ies and exome studies, comprising 281 candidate genes.
Results: Most patients (479/483) were treated with LCM in addition to other AEDs. 
Our results corroborate previous findings that patients with refractory genetic gener-
alized epilepsy (GGE) may respond to treatment with LCM. No clear clinical predic-
tors were identified. We then compared 73 lacosamide responders, defined as those 
experiencing greater than 75% seizure reduction or seizure freedom, to 495 nonre-
sponders (<25% seizure reduction). No variants reached the genome‐wide signifi-
cance threshold in our case‐control analysis.
Significance: No genetic predictor of lacosamide response was identified. Patients 
with refractory GGE might benefit from treatment with lacosamide.
K E Y W O R D S
GWAS, lacosamide, pharmacogenomics, pharmacoresistance, refractory
1 |  INTRODUCTION
About 25 antiepileptic drugs (AEDs) are available for the 
treatment of patients with epilepsy. Biomarkers to predict 
treatment success for specific AEDs are, however, missing. 
Clinicians base their choice of AEDs on factors such as syn-
drome, age, gender, co‐medications, comorbidities, and po-
tential side effects. Despite the increasing number of AEDs in 
recent years, up to one third of patients with epilepsy remain 
refractory to antiepileptic treatment and continue to experi-
ence seizures.1 AEDs are associated with multiple adverse 
drug reactions (ADRs), such as cutaneous reactions, psy-
chosis, electrolyte imbalance, and weight gain, which often 
limit their use in clinical practice. The idea of pharmaco-
genetic biomarkers to predict pharmacoresponse or adverse 
drug reactions is attractive. To date, however, reproduc-
ible discoveries in epilepsy pharmacogenetics are limited to 
mild to severe cutaneous ADRs to different sodium channel 
blockers. Polymorphisms in the HLA genes (HLA‐B15:02, 
HLA‐A31:01),2,3 cytochrome P450 genes (CYP2C9*3),4 and 
complement factors (CFHR4)5 have been shown to be associ-
ated with these adverse reactions.
Lacosamide (LCM) was first licensed in Europe in 2008 
and in the United States of America in 2009 for the treatment 
of focal‐onset seizures. LCM differs from other AEDs, such 
as carbamazepine, phenytoin, and lamotrigine, in that it is not 
a “traditional” sodium channel blocker. LCM enhances the 
slow inactivation of voltage‐gated sodium channels, resulting 
in the stabilization of hyperexcitable neuronal membranes 
and the inhibition of repetitive neuronal firing.6 For LCM, 
there are currently no pharmacogenetic data.
We report the findings of an observational study of LCM 
response in a large cohort of patients with epilepsy. We 
sought to identify the clinical predictors of response to LCM 
and to examine genetic variation in the predictions.
2 |  MATERIALS AND METHODS
2.1 | Recruitment and phenotypic 
information: EPIGEN cohort
Ethical approval was obtained from the ethics committee of 
each referral center. Informed consent was obtained from all 
Key Points
• We assessed the pharmacogenomics of lacosa-
mide response in a large cohort of people with re-
fractory epilepsy
• No genomic factors predicting response to lacosa-
mide were identified
• It is possible that lacosamide could be an option 
for some patients with refractory GGE.
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patients or where applicable, from their legal guardians, dur-
ing routine clinic attendance.
An initial cohort of 483 patients was used to investi-
gate the clinical predictors of LCM response. All pa-
tients were undergoing pharmacological treatment for 
refractory epilepsy. This was defined as having ongoing 
seizures despite treatment (current or prior) with two or 
more appropriate antiepileptic drugs at adequate doses.7 
Participants were recruited from four tertiary epilepsy re-
ferral centers: Beaumont Hospital and St. James’ Hospital, 
Dublin, Ireland (Royal College of Surgeons in Ireland); the 
National Hospital for Neurology & Neurosurgery (from 
the Queen Square and Chalfont sites), London, UK (UCL); 
Erasmus Hospital, Brussels, Belgium (Université Libre de 
Bruxelles); and Duke University Medical Centre, North 
Carolina, USA (Duke University). Patients were excluded 
if (a) they had a history of chronic alcohol or drug abuse 
within the previous three years and (b) they were suffering 
from any other clinically significant disease (eg, cancer, 
heart failure, and progressive neurological disorder).
This was an observational retrospective study, and pa-
tients were seen at varying intervals according to clini-
cal need at individual study sites. It thus was a "real‐life" 
clinical study where patients were managed according to 
detailed epileptology analysis at tertiary referral epilepsy 
centers, and patients were followed on the basis of routine 
clinical practice and need. Factors, such as determination 
of epilepsy syndrome classification, seizure frequency, and 
titration of drug, were determined by the treating epileptol-
ogist at each study site.
Phenotypic information including gender, maintenance 
dose of LCM, syndromic diagnosis, and presence or absence 
of any reported ADR was recorded. Syndrome diagnosis, 
based on the 2017 International League Against Epilepsy 
(ILAE) classification,8 was recorded into four separate cat-
egories: (a) focal epilepsy, (b) developmental and epileptic 
encephalopathies (DEE), (c) genetic generalized epilepsy 
(GGE), and (d) unclassifiable epilepsy.
Response to LCM was based on seizure frequency during 
treatment compared to baseline frequency. Baseline frequency 
was calculated as the average number of seizures per month 
in the three months prior to commencement of LCM. Patients 
were monitored for response to LCM over an 18‐month period. 
Seizure frequency was calculated as the average number of 
seizures per month during LCM treatment. All seizure types 
were taken into consideration when calculating the seizure fre-
quency. Response to LCM was calculated by comparing the 
seizure frequency during treatment to the baseline frequency.
Lacosamide response was divided into one of four catego-
ries: no response, seizure worsening, greater than 75% reduc-
tion in seizure frequency, and seizure freedom. We designed 
these categories to capture the major profiles of response typ-
ically seen in the clinic setting.
1. “Seizure freedom” was assigned to subjects who expe-
rienced no seizures for a minimum of 12  months while 
taking LCM.
2. Subjects who experienced a reduction in seizure fre-
quency of greater than 75% while on LCM treatment were 
assigned to the “greater than 75% reduction in seizure fre-
quency” category.
3. “No response” was assigned to those for whom the treat-
ing clinician felt there was no or little change in seizure 
frequency while on LCM compared to before treatment, 
that is, less than 25% seizure reduction.
4. “Seizures worsening” was assigned to those who experi-
enced an increase in seizure frequency during treatment 
with LCM, that is, greater than 50% increase in seizure 
frequency.
2.2 | Recruitment and phenotypic 
information: EpiPGX cohort
For the subsequent genetic analysis, 183 subjects from 
the EpiPGX study were included into the cohort (Table 
3). EpiPGX is a European‐wide epilepsy research partner-
ship under the European Commission Seventh Framework 
Protocol (FP7). Patients were recruited from five ter-
tiary epilepsy referral centers: Institute "G. Gaslini", 
University of Genova, Genoa, Italy; The Walton Centre 
NHS Foundation Trust, Liverpool, UK; Epilepsy Unit, 
West Glasgow ACH‐Yorkhill, UK; the University Hospital 
Bonn, Bonn, Germany; and the University Hospital 
Tübingen, Tübingen, Germany.
These additional 183 study subjects come from inde-
pendent nonoverlapping recruitment sites that comprise the 
EpiPGX study. These were included as an independent cohort 
to increase the study numbers and thus increase the power to 
detect potential genomic differences between the extremes of 
lacosamide responders (greater than 75% seizure reduction) 
on the one hand and nonresponders (less than 25% reduction) 
on the other.
2.3 | Testing for genetic 
predictors of response
Genotype data were available on 570 patients. Samples 
were genotyped either at Duke University Centre for Human 
Genome Variation (NC, USA) on the Illumina Human610 
beadchip or at DeCODE genetics (Reykjavik, Iceland) on the 
Illumina HumanOmniExpress beadchip platform. Imputation 
to the phase 1v3 (March 2012) 1000 Genomes reference 
panel was performed as follows: genotype data were fil-
tered to remove SNPs with low call rate (>5% missingness), 
Hardy‐Weinberg equilibrium (P  <  10−6), and <1% minor 
allele frequency (MAF). Duplicates were removed while 
gender mismatches were checked and errors resolved. Using 
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this subset of markers, heterozygosity and identity by state 
(IBS) were calculated in order to remove all samples with 
outlying heterozygosity values (>5 standard deviations from 
the median of the whole sample) and one half of all sample 
pairs with >0.9 IBS. Sample ethnicity was assessed through 
STRUCTURE,9 and only samples matching European an-
cestry were included (CEU  >  90%, as determined from 
HapMap populations). Genotype data were aligned to posi-
tive strand and separated by chromosome prior to phasing 
with SHAPEIT.10 Phased chromosomes were imputed to the 
1000 Genomes phase 1v3 reference panel with IMPUTE2.11 
Imputed variants were filtered to only those with high call 
rate (>0.9), high confidence score (info > 0.95), and com-
mon MAF (>2%). Genotype data were cleaned using stand-
ard quality control metrics with PLINK,12 GCTA,13 and 
GTOOL.
We also investigated the contribution of rarer genetic 
variation from whole exome sequencing data within the same 
case‐control response groups above. A total of 110 sam-
ples were sequenced at Duke University Centre for Human 
Genome Variation (NC, USA) using the Roche Nimblgen 
SeqCap EZ Exome target enrichment platform. A further 66 
samples were sequenced at DeCODE genetics (Reykjavik, 
Iceland) using the Illumina Nextera target enrichment plat-
form. Individual FASTQ files were aligned to human genome 
reference b37 with Burrows‐Wheeler Aligner. Resultant BAM 
files were then processed through the GATK Best Practices 
pipeline to remove duplicate reads, align indels, and recali-
brate base quality scores to generate individual genomeVCF 
files. The cohort of genomeVCFs was then joint‐genotyped 
into a single multisample VCF file. Variant annotation was 
performed with ANNOVAR. Only sites with minimum 10× 
coverage across all subjects were considered for analysis.
2.4 | Statistical methods
Multiple logistic regression of clinical covariates was used to 
test for gender and ILAE diagnosis as predictors of treatment 
outcome. A logistic regression model was used to test dose as 
a predictor of treatment outcome and to test gender as a pre-
dictor of reported ADR. Statistical analysis was performed 
with the use of Stata® (version IC 13) software package.
We defined cases as any subject with a broadly positive 
response (greater than 75% seizure reduction or seizure free-
dom), while controls were defined as those with no response 
or seizures worsening.
We performed a primary case‐control association test in 
PLINK using a logistic regression model, with syndromic 
diagnosis and five principal components as covariates, pool-
ing samples from EPIGEN and EpiPGX. We subsequently 
performed the following secondary subanalyses: seizure 
freedom vs no response, greater than 75% reduction of sei-
zure frequency vs no response, and seizures worsening vs no 
response. Drug dosage data were missing in >10% of sam-
ples and were therefore not included as a covariate. A mini-
mum minor allele frequency threshold of 2% was applied to 
genotype data. We estimated that the study had 80% power 
to detect a genetic predictor of relative risk (approximated to 
odds ratio) ≥ 6 with an allele frequency ≥ 2% and an alpha 
level of 5 × 10−8. The study power improves with increasing 
minor allele frequency (Figure S2).
In our exome analysis, we performed the same set of pri-
mary and secondary case‐control analyses as described above. 
We included any functional variant (missense, nonsense, frame-
shift, and splice site variants) with a maximum population‐wide 
minor allele frequency of 2% in gnomAD. When analyzing, we 
collapsed qualifying variants per gene and performed a SKAT‐O 
test with syndromic diagnosis, sequencing site, and five prin-
cipal components as covariates in the model. We considered a 
total of 281 genes composed of 267 genes involved in absorp-
tion, distribution, metabolism and excretion (ADME) and 14 so-
dium channel genes (the full list of genes can be found in Table 
S1). We excluded genes with less than two polymorphic variants 
in our cohort. We applied a Bonferroni corrected significance 
threshold of P = 5.9 × 10‐05 to account for the 281 genes as-
sessed in the three logistic regression models listed above.
3 |  RESULTS
3.1 | Clinical predictors
A total of 483 patients (276 females) were included in the 
study from four centers as part of the EPIGEN consortium. 
The majority of them (n = 479) were treated with LCM in 
addition to other AEDs.
The majority of patients had focal epilepsy (91%), while 
4% had genetic generalized epilepsy, 3% had developmental 
and epileptic encephalopathies, and 2% had an unclassifiable 
epilepsy diagnosis (Table 1).
The response categories for each tertiary referral center 
are shown in Table 1. Seizure freedom rate ranged from 1% to 
9% across the four referral centers, with an average of 4% for 
the combined cohort. Overall, 13% of patients had a positive 
response to LCM treatment (seizure freedom or greater than 
75% reduction in seizure frequency). Eight percent had an 
increase of seizures during LCM treatment (range 2%‐15%), 
while 79% of patients showed no response to LCM treatment 
(range 66%‐89%).
Maintenance dose ranged from 25 to 800 mg/d, with the 
majority (n = 139) maintained on 400 mg/d of LCM (Figure 
1A). The average maintenance dose was compared across the 
four response categories (Figure 1B). Patients who had sei-
zure aggravation while on LCM had the lowest average main-
tenance dose compared to the other response groups. Patients 
who had a greater than 75% reduction in seizure frequency 
had the highest average maintenance dose.
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3.1.1 | Gender as a predictor of response
To test whether gender was a significant predictor of re-
sponse to LCM treatment, we developed a logistic regression 
model with response as the dependent variable, and gender 
and ILAE syndromic diagnosis as the predictor variables. For 
each test, the specific response category of LCM treatment 
(seizures worsening/greater than 75% reduction in seizure 
frequency/seizure freedom) was compared to the category 
of “no response to LCM treatment.” Gender did not emerge 
as a significant predictor for any of the response categories 
(seizures worsening, P =  .225; greater than 75% reduction 
in seizure frequency, P = .994; seizure freedom, P = .073).
3.1.2 | Syndromic diagnosis as a 
predictor of response
As LCM is licensed for the treatment of focal‐onset seizures, 
we wished to test whether other syndromic categories (ie, 
GGE, DEE, and unclassifiable) responded in a different way 
compared to the “focal” category. We therefore compared 
response profiles of each of the generalized and unclassified 
T A B L E  1  Breakdown of syndromic epilepsy diagnosis and response categories for each of the four tertiary referral centers
Dublin London Brussels North Carolina Combined cohort
Epilepsy diagnosis
Focal epilepsy of known etiology 51 (57%) 177 (72%) 31 (61%) 47 (49%) 306 (64%)
Focal epilepsy of unknown etiology 29 (33%) 52 (21%) 18 (35%) 33 (35%) 132 (27%)
Developmental and/or epileptic 
encephalopathies
5 (6%) 8 (3%) 0 3 (3%) 16 (3%)
Genetic generalized epilepsy 3 (3%) 6 (2%) 0 9 (9%) 18 (4%)
Unclassifiable epilepsy 1 (1%) 4 (2%) 2 (4%) 4 (4%) 11 (2%)
Total 89 247 51 96 483 (100%)
Response categories
Seizure freedom 3 (3%) 3 (1%) 3 (6%) 9 (9%) 18 (4%)
≥75% reduction in seizure frequency 10 (11%) 8 (3%) 5 (10%) 22 (23%) 45 (9%)
No response 65 (74%) 219 (89%) 35 (69%) 63 (66%) 382 (79%)
Seizures worsening 11 (12%) 17 (7%) 8 (15%) 2 (2%) 38 (8%)
Total 89 247 51 96 483
Note: Percentage of each syndrome/ response category for each site and the combined cohort are shown in parenthesis.
F I G U R E  1  Manhattan plot and quantile‐quantile plot for genome‐wide association analysis of broad response vs no response or seizures 
worsening [Genomic Inflation Factor = 1.01]
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groups, to focal (known and unknown etiology) epilepsy. To 
test diagnosis as a predictor of LCM response, each of the 
response categories (seizures worsening/greater than 75% re-
duction in seizure frequency/seizure freedom) was compared 
to the “no response” category. Syndromic diagnosis was taken 
into consideration for each of these response comparisons 
(Table 2). The results suggest that patients with GGE were 
five times more likely to respond to treatment with LCM, 
when compared to patients with a focal diagnosis (P = .049). 
Syndromic diagnosis did not emerge as a significant clinical 
predictor for patients who experienced a worsening seizure 
activity following treatment with LCM.
3.2 | Genomic predictors
Genotype data were available on 570 patients for the GWAS 
analysis; 387 patients from the EPIGEN cohort; and a further 
183 patients from the EpiPGX cohort. Following genotype 
imputation and quality control, there were genotype dosage 
data for 5,205,884 SNP markers. Table 3 shows the break-
down of response categories for both cohorts.
To test for association with broad response to LCM, we 
carried out a genome‐wide analysis of the broad response 
group (n = 75) compared to patients with no response or sei-
zures worsening (n = 495). We did not detect any variants 
satisfying our threshold for genome‐wide significance (Figure 
1). Further comparisons between smaller groups also did not 
yield significant results (see Figure S3).
Following quality control of exome sequences, there were 
160 subjects available for analysis. The results from our 
SKAT‐O tests did not reveal a significant contribution of rare 
variants to LCM response after correction for multiple test-
ing (Figure 2 and Table 4). The full set of test results can be 
found in the supplements.
4 |  DISCUSSION
In our large cohort, 4% became seizure‐free following treat-
ment with LCM, similar to that seen previously, where 3.4% 
of subjects had achieved seizure freedom at three months 
of evaluation.14 Most studies, including the three regula-
tory randomized controlled trials, evaluated the number 
and proportion of subjects who had a 50% reduction in sei-
zure frequency, known as 50% responders 15‒20 (reviewed 
in Ref.21), and reported between 18% and 69% of subjects 
meeting this criterion.21 We evaluated response as greater 
than 75% reduction in seizure frequency (to enrich the par-
tial response group for genetic analysis), and thus, com-
parison with other studies is not possible for this response 
Response EPIGEN EpiPGX Total GWAS Total WES
Seizure freedom 15 14 29 25
Greater than 75% reduction 
in seizure frequency
31 15 46 14
No response 305 143 448 90
Seizures worsening 36 11 47 31
Subtotal 387 183 570 160
Abbreviation: WES, whole exome sequencing.
T A B L E  3  Sample count for 
lacosamide response categories in EPIGEN 
and EpiPGX
Response Diagnosis n RRR (95% CI) P
Seizure freedom DEE 0 na na
GGE 2 5.06 (1.01‐25.22) .049*
Unclassifiable epilepsy 2 8.42 (1.55‐45.67) .014*
Greater than 75% reduction 
in seizure frequency
DEE 2 1.60 (0.34‐7.44) .548
GGE 4 4.24 (1.24‐14.42) .021*
Unclassifiable epilepsy 1 1.73 (0.20‐14.91) .618
Seizures worsening DEE 1 0.79 (0.98‐6.44) .830
GGE 2 1.73 (0.35‐8.60) .500
Unclassifiable epilepsy 1 3.45 (0.64‐18.52) .149
Note: Focal epilepsy was used as the base variable for diagnosis. Response to LCM treatment (seizures wors-
ening/≥75% reduction in seizure frequency/seizure freedom) was compared to the “no response” category. No 
patient with DEE achieved seizure freedom (na = not applicable). Values that reached significance (*P < .05) 
are shown in bold.
Abbreviations: CI, confidence interval; RRR, relative risk ratio for variables associated with LCM response.
T A B L E  2  Diagnosis as a predictor of 
LCM response
   | 569HEAVIN Et Al.
group. Nonresponders accounted for up to a third of subjects 
in previous studies.21 Our subcohorts of nonresponders (no 
response and seizure worsening) accounted for 87% of our 
cases. This difference could be explained by the fact that 
our cohorts were derived from tertiary referral centers which 
handle many patients with highly refractory epilepsies. As 
in this study, previous studies reported few subjects that had 
seizure aggravation.14 In our cohort, the worsening cases 
had the lowest average LCM dose, some cases even below 
100 mg. It is probable that seizure aggravation was due to 
other unknown factors or was just observed by chance as 
result of natural fluctuation of seizure frequency and was not 
an immediate consequence of LCM treatment.
This study looked at gender and syndrome diagnosis as 
clinical predictors of response. Gender was not predictive of 
LCM response in our data. This finding, together with the evi-
dence that gender does not affect the pharmacokinetic profile of 
LCM,22 suggests gender is not playing a role in the varying re-
sponse of patients to LCM. Many studies have evaluated the ef-
ficacy and safety of LCM in adults with refractory epilepsy and 
focal seizures only (reviewed in Paquette et al15). In a separate 
study evaluating the safety and efficacy of LCM in both pedi-
atric and adult populations, patients with focal and generalized 
epilepsy were included.14 The clinical outcome results in our 
patients with refractory focal epilepsy contrast with another 
real‐world multisite observational study from Germany of the 
use of lacosamide added to one prior antiepileptic drug in 520 
patients, in which 63.8% of patients had a greater than 75% 
seizure reduction, reflecting a presumably much less refractory 
population.23 While LCM has been shown to be effective in 
focal epilepsy and status epilepticus, the use of LCM in the 
treatment of refractory GGE is limited to smaller studies and 
case series but showed rather positive results.19,24‒26 Patients 
with GGE responded well to LCM treatment compared to 
those with focal epilepsy (Table 3). Our cohort of patients with 
GGE is small, and our study was observational, unblended, and 
not designed to test efficacy by syndrome. Therefore, these re-
sults have to be considered with caution. Nonetheless, they are 
suggestive that patients with GGE may benefit from treatment 
with LCM and are in line with previous studies.
Genome‐wide meta‐analysis did not identify a significant 
contribution of common or rare genetic variants to lacosamide 
response satisfying our threshold for significance, for any of the 
response groups (Figures 1,2) despite 80% power to detect a ge-
netic predictor of relative risk (approximated to odds ratio) ≥ 6 
with an allele frequency ≥ 2%. These findings underline that 
pharmacoresistance constitutes a complex trait that is not solely 
driven by one or a few genetic factors. Larger cohorts of pa-
tients could help to further elucidate this question. More novel 
analysis techniques such as the polygenic risk score27 or the 
polygenic transmission disequilibrium test28 could also help to 
elucidate the role of common variants in future studies.
A limitation of our study is that it is a biased observational 
study in patients with refractory disease attending tertiary re-
ferral centers. However, refractory patients who may respond 
to a newly introduced AED such as lacosamide might have 
novel pharmacogenomic factors that may be identifiable even 
in a relatively small cohort of patients. In this type of study 
in a refractory cohort, a small group of patients with previ-
ously drug‐resistant epilepsy who become seizure‐free or 
whose seizure control markedly improves when another new 
drug is added to their treatment regimen (a group that might 
F I G U R E  2  Q‐Q plot of SKAT‐O test of candidate gene‐set 
association with LCM response
Analysis Gene No. SNV Q Rho P
Broad response vs no 
response
CYP24A1 2 426.474 1 .007
SLC22A16 2 597.149 0 .037
CYP3A7 2 247.833 0 .049
ALDH9A1 4 606.731 0 .050
FMO3 2 433.141 1 .055
GSTM5 2 565.228 1 .069
Abbreviations: Q, SKAT test statistic; P, uncorrected significance value; Rho, 0 or 1 for SKAT or burden test, 
respectively; SNV, number of polymorphic markers in gene.
T A B L E  4  Top SKAT‐O results for 
gene‐set analyses of each response group
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be termed “unexpected responders”) might be a cohort in 
which we might gain important pharmacogenomic response 
insights. We believe that our study is an important proof‐of‐
principle pharmacogenomic approach that could be adopted 
by the epilepsy clinical trial community and industry partners 
to incorporate into future randomized controlled trials of new 
AEDs. Therefore, further such pharmacogenomic response 
studies would also ideally be performed in either new‐onset 
patients or patients earlier in the course of their epilepsy.
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